InvAscent acquired RPG Active Pharma in a carve-out transaction completed on July 31, 2026. The deal involved InvAscent purchasing 100% of the target company's shares, focusing on separating and focusing on its active pharmaceutical ingredient (API) business.
| Acquirer | InvAscent (IN) |
|---|---|
| Target | RPG Active Pharma (IN) |
| Type of Deal | Carve-out |
| Closing Date | July 31, 2026 |
| Deal Value | Undisclosed |
| Purchase Stake | 100.0% |
| Sell-side Advisors | Khaitan & Co |
| Buy-side Advisors | Not disclosed |
| Sell-side Legal Advisors | Khaitan & Co |
| Buy-side Legal Advisors | Khaitan & Co |
The transaction aims to streamline RPG Life Sciences Ltd's portfolio and enable a more focused approach towards its API business. This carve-out allows InvAscent to gain control over the API division, which has been separated from RPG Life Sciences' broader operations.
Deal Mechanics
RPG Active Pharma was carved out of its parent company RPG Life Sciences Ltd with legal support provided by Khaitan & Co. The deal's financial terms were not disclosed but the separation process involved a comprehensive restructuring and review of intellectual property, real estate assets, and other key components.
Strategic Rationale
The rationale behind this transaction is to create a dedicated platform for API manufacturing within RPG Life Sciences' portfolio. This carve-out will allow RPG Active Pharma to operate independently with focused management attention on the growth of its pharmaceutical ingredient business, while also benefiting from InvAscent's investment and operational expertise.
Financial Context
The financial details of this deal were not disclosed by either party involved, including any purchase price or key terms. However, Khaitan & Co provided legal counsel for RPG Life Sciences during the restructuring process to ensure compliance with regulatory requirements and facilitate a smooth transition.
Advisors
RPG Life Sciences Ltd received financial and legal advisory services from Khaitan & Co in executing this carve-out transaction. The deal team included Haigreve Khaitan (Managing Partner), Shishir Jose Vayttaden (Partner), Aditi Singhvi (Partner) and Bhaskar Vishwajeet (Associate). Additional support was provided by real estate specialists Harsh Parikh, Rahul Sunil Agarwal and Raghav Manojkumar Pareek as well as intellectual property experts Nirupam Lodha, Toshani Mukherjee and Rebecca Cardoso.
Outlook
The carve-out is expected to enhance the operational efficiency of RPG Active Pharma by allowing it greater autonomy in strategic decision-making processes. For InvAscent, this deal represents an opportunity to enter a promising segment within the healthcare industry with significant growth potential.